Bleeding Disorders Market By Disease Type, By Treatment Type, By Distribution Channel : Global Opportunity Analysis and Industry Forecast, 2023-2032

Description

List of Tables

According to a new report published by Allied Market Research, titled, "Bleeding Disorders Market," The bleeding disorders market was valued at $13.8 billion in 2022, and is estimated to reach $26 billion by 2032, growing at a CAGR of 6.6% from 2023 to 2032. A bleeding disorder is a medical condition characterized by inability of a person to form blood clots properly. Blood clots are essential in stopping bleeding after an injury or trauma. Bleeding disorders may lead to excessive bleeding, even with minor injuries, and may also cause internal bleeding in some cases.

Bleeding disorders are a group of conditions characterized by abnormal bleeding due to the deficiency or dysfunction of certain clotting factors in the blood. Normally, when a person experiences an injury or cut, the body forms a clot to stop bleeding. However, in a person with a bleeding disorder, this process is impaired or absent, which may lead to abnormal or excessive bleeding. Hemophilia is the most well-known and common bleeding disorder, which affects mostly males and may result in serious and life-threatening bleeding episodes. Von Willebrand disease is another common bleeding disorder that affects both males and females and may lead to prolonged bleeding after injury or surgery.

Major factors that drive the growth of the bleeding disorders market include rapid advancements in treatment of bleeding disorders; increase in number of patients suffering from hemophilia A, hemophilia B, and other bleeding disorders. For instance, according to the Centers for Disease Control and Prevention (CDC) 2022, 33,000 males in the U.S. live with the bleeding disorder.

Furthermore, favorable government initiatives for hemophilia management, increase in number of awareness programs regarding bleeding disorder treatment and rise in number of clinical trials for the development of antihemophilic drugs boost the growth of bleeding disorders market. In addition, the increase in target population, increase in diagnosis rate, and surge in the use of prophylactic treatment for hemophilia propel the market growth.

However, the high cost of hemophilia treatment, and serious adverse effects associated with plasma derived products are expected to restrict the growth of bleeding disorders market. On the contrary, surge in healthcare expenditure, and unmet medical demands to get better treatment options for hemophilia in developing countries are expected to create immense opportunities for the expansion of the global market in the future.

The bleeding disorders market is segmented on the basis of disease type, treatment type, distribution channel and region. On the basis of disease type, the market is classified into hemophilia A, hemophilia B, Von Willebrand disease and others. On the basis of treatment type, the market is classified into factor replacement therapy, and drug therapy (desmopressin, antifibrinolytics, fibrin sealant). The factor replacement therapy segment is further bifurcated into plasma-derived coagulation factor concentrates, and recombinant coagulation factor concentrates. On the basis of distribution channel, the bleeding disorders market is segmented into hospital pharmacies, drugs stores and retail pharmacies, and online pharmacies. On the basis of region, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and Rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea, and Rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and Rest of LAMEA).

Major players profiled in the report are Bayer AG, CSL Ltd. (CSL Behring), F. Hoffmann-La Roche AG, Grifols, S.A., Medexus Pharma, Inc., Novo Nordisk A/S, Octapharma AG, Pfizer Inc., SANOFI CORPORATION, and Takeda Pharmaceutical Company Limited. The major players in the market have adopted investment, partnership and product approvals as key developmental strategies to improve the product portfolio of the bleeding disorders market.

Key Benefits For Stakeholders

This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the bleeding disorders market analysis from 2022 to 2032 to identify the prevailing bleeding disorders market opportunities.
The market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the bleeding disorders market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global bleeding disorders market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Disease Type

Hemophilia A
Hemophilia B
Von Willebrand Disease
Others

By Treatment Type

Factor Replacement Therapy
- Type
- Recombinant coagulation factor concentrates
- Plasma derived coagulation factor concentrates
Drug Therapy

By Distribution Channel

Hospital Pharmacies
Drug stores and retail pharmacies
Online pharmacies

By Region

North America
- U.S.
- Canada
- Mexico
Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
Asia-Pacific
- Japan
- China
- Australia
- India
- South Korea
- Rest of Asia-Pacific
LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA

Key Market Players:

Medexus Pharma, Inc.
Bayer AG
Novo Nordisk A/S
Grifols, S.A.
Octapharma AG
Takeda Pharmaceutical Company Limited
CSL Limited
Pfizer Inc.
Sanofi
F. Hoffmann-La Roche Ltd.

Product Code: A02466

CHAPTER 1: INTRODUCTION

1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research Methodology
- 1.4.1. Primary research
- 1.4.2. Secondary research
- 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

2.1. CXO Perspective

CHAPTER 3: MARKET OVERVIEW

3.1. Market definition and scope
3.2. Key findings
- 3.2.1. Top impacting factors
- 3.2.2. Top investment pockets
3.3. Porter's five forces analysis
- 3.3.1. Bargaining power of suppliers
- 3.3.2. Bargaining power of buyers
- 3.3.3. Threat of substitutes
- 3.3.4. Threat of new entrants
- 3.3.5. Intensity of rivalry
3.4. Market dynamics
- 3.4.1. Drivers
  - 3.4.1.1. Rise in prevalence of hemophilia
  - 3.4.1.2. Technological advancements in treatment of hemophilia
  - 3.4.1.3. Favorable government initiatives for hemophilia management

3.4.2. Restraints
- 3.4.2.1. High cost of bleeding disorders treatments

3.4.3. Opportunities
- 3.4.3.1. Rise in awareness about bleeding disorders in developing countries

3.5. COVID-19 Impact Analysis on the market

CHAPTER 4: BLEEDING DISORDERS MARKET, BY DISEASE TYPE

4.1. Overview
- 4.1.1. Market size and forecast
4.2. Hemophilia A
- 4.2.1. Key market trends, growth factors and opportunities
- 4.2.2. Market size and forecast, by region
- 4.2.3. Market share analysis by country
4.3. Hemophilia B
- 4.3.1. Key market trends, growth factors and opportunities
- 4.3.2. Market size and forecast, by region
- 4.3.3. Market share analysis by country
4.4. Von Willebrand Disease
- 4.4.1. Key market trends, growth factors and opportunities
- 4.4.2. Market size and forecast, by region
- 4.4.3. Market share analysis by country
4.5. Others
- 4.5.1. Key market trends, growth factors and opportunities
- 4.5.2. Market size and forecast, by region
- 4.5.3. Market share analysis by country

CHAPTER 5: BLEEDING DISORDERS MARKET, BY TREATMENT TYPE

5.1. Overview
- 5.1.1. Market size and forecast
5.2. Factor Replacement Therapy
- 5.2.1. Key market trends, growth factors and opportunities
- 5.2.2. Market size and forecast, by region
- 5.2.3. Market share analysis by country
- 5.2.4. Factor Replacement Therapy Bleeding Disorders Market by Type
5.3. Drug Therapy
- 5.3.1. Key market trends, growth factors and opportunities
- 5.3.2. Market size and forecast, by region
- 5.3.3. Market share analysis by country

CHAPTER 6: BLEEDING DISORDERS MARKET, BY DISTRIBUTION CHANNEL

6.1. Overview
- 6.1.1. Market size and forecast
6.2. Hospital Pharmacies
- 6.2.1. Key market trends, growth factors and opportunities
- 6.2.2. Market size and forecast, by region
- 6.2.3. Market share analysis by country
6.3. Drug stores and retail pharmacies
- 6.3.1. Key market trends, growth factors and opportunities
- 6.3.2. Market size and forecast, by region
- 6.3.3. Market share analysis by country
6.4. Online pharmacies
- 6.4.1. Key market trends, growth factors and opportunities
- 6.4.2. Market size and forecast, by region
- 6.4.3. Market share analysis by country

CHAPTER 7: BLEEDING DISORDERS MARKET, BY REGION

7.1. Overview
- 7.1.1. Market size and forecast By Region
7.2. North America
- 7.2.1. Key trends and opportunities
- 7.2.2. Market size and forecast, by Disease Type
- 7.2.3. Market size and forecast, by Treatment Type
- 7.2.4. Market size and forecast, by Distribution Channel
- 7.2.5. Market size and forecast, by country
  - 7.2.5.1. U.S.
  - 7.2.5.1.1. Key market trends, growth factors and opportunities
  - 7.2.5.1.2. Market size and forecast, by Disease Type
  - 7.2.5.1.3. Market size and forecast, by Treatment Type
  - 7.2.5.1.4. Market size and forecast, by Distribution Channel
  - 7.2.5.2. Canada
  - 7.2.5.2.1. Key market trends, growth factors and opportunities
  - 7.2.5.2.2. Market size and forecast, by Disease Type
  - 7.2.5.2.3. Market size and forecast, by Treatment Type
  - 7.2.5.2.4. Market size and forecast, by Distribution Channel
  - 7.2.5.3. Mexico
  - 7.2.5.3.1. Key market trends, growth factors and opportunities
  - 7.2.5.3.2. Market size and forecast, by Disease Type
  - 7.2.5.3.3. Market size and forecast, by Treatment Type
  - 7.2.5.3.4. Market size and forecast, by Distribution Channel
7.3. Europe
- 7.3.1. Key trends and opportunities
- 7.3.2. Market size and forecast, by Disease Type
- 7.3.3. Market size and forecast, by Treatment Type
- 7.3.4. Market size and forecast, by Distribution Channel
- 7.3.5. Market size and forecast, by country
  - 7.3.5.1. Germany
  - 7.3.5.1.1. Key market trends, growth factors and opportunities
  - 7.3.5.1.2. Market size and forecast, by Disease Type
  - 7.3.5.1.3. Market size and forecast, by Treatment Type
  - 7.3.5.1.4. Market size and forecast, by Distribution Channel
  - 7.3.5.2. France
  - 7.3.5.2.1. Key market trends, growth factors and opportunities
  - 7.3.5.2.2. Market size and forecast, by Disease Type
  - 7.3.5.2.3. Market size and forecast, by Treatment Type
  - 7.3.5.2.4. Market size and forecast, by Distribution Channel
  - 7.3.5.3. UK
  - 7.3.5.3.1. Key market trends, growth factors and opportunities
  - 7.3.5.3.2. Market size and forecast, by Disease Type
  - 7.3.5.3.3. Market size and forecast, by Treatment Type
  - 7.3.5.3.4. Market size and forecast, by Distribution Channel
  - 7.3.5.4. Italy
  - 7.3.5.4.1. Key market trends, growth factors and opportunities
  - 7.3.5.4.2. Market size and forecast, by Disease Type
  - 7.3.5.4.3. Market size and forecast, by Treatment Type
  - 7.3.5.4.4. Market size and forecast, by Distribution Channel
  - 7.3.5.5. Spain
  - 7.3.5.5.1. Key market trends, growth factors and opportunities
  - 7.3.5.5.2. Market size and forecast, by Disease Type
  - 7.3.5.5.3. Market size and forecast, by Treatment Type
  - 7.3.5.5.4. Market size and forecast, by Distribution Channel
  - 7.3.5.6. Rest of Europe
  - 7.3.5.6.1. Key market trends, growth factors and opportunities
  - 7.3.5.6.2. Market size and forecast, by Disease Type
  - 7.3.5.6.3. Market size and forecast, by Treatment Type
  - 7.3.5.6.4. Market size and forecast, by Distribution Channel
7.4. Asia-Pacific
- 7.4.1. Key trends and opportunities
- 7.4.2. Market size and forecast, by Disease Type
- 7.4.3. Market size and forecast, by Treatment Type
- 7.4.4. Market size and forecast, by Distribution Channel
- 7.4.5. Market size and forecast, by country
  - 7.4.5.1. Japan
  - 7.4.5.1.1. Key market trends, growth factors and opportunities
  - 7.4.5.1.2. Market size and forecast, by Disease Type
  - 7.4.5.1.3. Market size and forecast, by Treatment Type
  - 7.4.5.1.4. Market size and forecast, by Distribution Channel
  - 7.4.5.2. China
  - 7.4.5.2.1. Key market trends, growth factors and opportunities
  - 7.4.5.2.2. Market size and forecast, by Disease Type
  - 7.4.5.2.3. Market size and forecast, by Treatment Type
  - 7.4.5.2.4. Market size and forecast, by Distribution Channel
  - 7.4.5.3. Australia
  - 7.4.5.3.1. Key market trends, growth factors and opportunities
  - 7.4.5.3.2. Market size and forecast, by Disease Type
  - 7.4.5.3.3. Market size and forecast, by Treatment Type
  - 7.4.5.3.4. Market size and forecast, by Distribution Channel
  - 7.4.5.4. India
  - 7.4.5.4.1. Key market trends, growth factors and opportunities
  - 7.4.5.4.2. Market size and forecast, by Disease Type
  - 7.4.5.4.3. Market size and forecast, by Treatment Type
  - 7.4.5.4.4. Market size and forecast, by Distribution Channel
  - 7.4.5.5. South Korea
  - 7.4.5.5.1. Key market trends, growth factors and opportunities
  - 7.4.5.5.2. Market size and forecast, by Disease Type
  - 7.4.5.5.3. Market size and forecast, by Treatment Type
  - 7.4.5.5.4. Market size and forecast, by Distribution Channel
  - 7.4.5.6. Rest of Asia-Pacific
  - 7.4.5.6.1. Key market trends, growth factors and opportunities
  - 7.4.5.6.2. Market size and forecast, by Disease Type
  - 7.4.5.6.3. Market size and forecast, by Treatment Type
  - 7.4.5.6.4. Market size and forecast, by Distribution Channel
7.5. LAMEA
- 7.5.1. Key trends and opportunities
- 7.5.2. Market size and forecast, by Disease Type
- 7.5.3. Market size and forecast, by Treatment Type
- 7.5.4. Market size and forecast, by Distribution Channel
- 7.5.5. Market size and forecast, by country
  - 7.5.5.1. Brazil
  - 7.5.5.1.1. Key market trends, growth factors and opportunities
  - 7.5.5.1.2. Market size and forecast, by Disease Type
  - 7.5.5.1.3. Market size and forecast, by Treatment Type
  - 7.5.5.1.4. Market size and forecast, by Distribution Channel
  - 7.5.5.2. Saudi Arabia
  - 7.5.5.2.1. Key market trends, growth factors and opportunities
  - 7.5.5.2.2. Market size and forecast, by Disease Type
  - 7.5.5.2.3. Market size and forecast, by Treatment Type
  - 7.5.5.2.4. Market size and forecast, by Distribution Channel
  - 7.5.5.3. South Africa
  - 7.5.5.3.1. Key market trends, growth factors and opportunities
  - 7.5.5.3.2. Market size and forecast, by Disease Type
  - 7.5.5.3.3. Market size and forecast, by Treatment Type
  - 7.5.5.3.4. Market size and forecast, by Distribution Channel
  - 7.5.5.4. Rest of LAMEA
  - 7.5.5.4.1. Key market trends, growth factors and opportunities
  - 7.5.5.4.2. Market size and forecast, by Disease Type
  - 7.5.5.4.3. Market size and forecast, by Treatment Type
  - 7.5.5.4.4. Market size and forecast, by Distribution Channel

CHAPTER 8: COMPETITIVE LANDSCAPE

8.1. Introduction
8.2. Top winning strategies
8.3. Product Mapping of Top 10 Player
8.4. Competitive Dashboard
8.5. Competitive Heatmap
8.6. Top player positioning, 2022

CHAPTER 9: COMPANY PROFILES

9.1. Pfizer Inc.
- 9.1.1. Company overview
- 9.1.2. Key Executives
- 9.1.3. Company snapshot
- 9.1.4. Operating business segments
- 9.1.5. Product portfolio
- 9.1.6. Business performance
- 9.1.7. Key strategic moves and developments
9.2. Novo Nordisk A/S
- 9.2.1. Company overview
- 9.2.2. Key Executives
- 9.2.3. Company snapshot
- 9.2.4. Operating business segments
- 9.2.5. Product portfolio
- 9.2.6. Business performance
- 9.2.7. Key strategic moves and developments
9.3. Bayer AG
- 9.3.1. Company overview
- 9.3.2. Key Executives
- 9.3.3. Company snapshot
- 9.3.4. Operating business segments
- 9.3.5. Product portfolio
- 9.3.6. Business performance
9.4. Octapharma AG
- 9.4.1. Company overview
- 9.4.2. Key Executives
- 9.4.3. Company snapshot
- 9.4.4. Operating business segments
- 9.4.5. Product portfolio
- 9.4.6. Business performance
- 9.4.7. Key strategic moves and developments
9.5. Sanofi
- 9.5.1. Company overview
- 9.5.2. Key Executives
- 9.5.3. Company snapshot
- 9.5.4. Operating business segments
- 9.5.5. Product portfolio
- 9.5.6. Business performance
- 9.5.7. Key strategic moves and developments
9.6. Medexus Pharma, Inc.
- 9.6.1. Company overview
- 9.6.2. Key Executives
- 9.6.3. Company snapshot
- 9.6.4. Operating business segments
- 9.6.5. Product portfolio
- 9.6.6. Business performance
- 9.6.7. Key strategic moves and developments
9.7. Grifols, S.A.
- 9.7.1. Company overview
- 9.7.2. Key Executives
- 9.7.3. Company snapshot
- 9.7.4. Operating business segments
- 9.7.5. Product portfolio
- 9.7.6. Business performance
- 9.7.7. Key strategic moves and developments
9.8. F. Hoffmann-La Roche Ltd.
- 9.8.1. Company overview
- 9.8.2. Key Executives
- 9.8.3. Company snapshot
- 9.8.4. Operating business segments
- 9.8.5. Product portfolio
- 9.8.6. Business performance
- 9.8.7. Key strategic moves and developments
9.9. CSL Limited
- 9.9.1. Company overview
- 9.9.2. Key Executives
- 9.9.3. Company snapshot
- 9.9.4. Operating business segments
- 9.9.5. Product portfolio
- 9.9.6. Business performance
- 9.9.7. Key strategic moves and developments
9.10. Takeda Pharmaceutical Company Limited
- 9.10.1. Company overview
- 9.10.2. Key Executives
- 9.10.3. Company snapshot
- 9.10.4. Operating business segments
- 9.10.5. Product portfolio
- 9.10.6. Business performance
- 9.10.7. Key strategic moves and developments